You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

251 Results
Guidelines and Advice
Status: Current
ID: N/A
Version: N/A
Oct 2019
Guidelines and Advice
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Intent: Adjuvant, Curative
Nov 2019
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Dec 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma
Exceptional Access Program
    pomalidomide - In combination with isatuximab and dexamethasone for relapsed or refractory multiple myeloma, according to specific criteria
Feb 2024
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma
New Drug Funding Program
    Isatuximab and Carfilzomib - In Combination with Dexamethasone for Relapsed or Refractory Multiple Myeloma
Feb 2024
Drug
Other Name(s): Kyprolis®
Feb 2024
Guidelines and Advice

Pages